Premium
Effects of rasagiline on the progression of nonmotor scores of the MDS‐UPDRS
Author(s) -
Poewe Werner,
Hauser Robert A.,
Lang Anthony
Publication year - 2015
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.26124
Subject(s) - rasagiline , placebo , placebo group , parkinson's disease , medicine , clinical trial , disease , pathology , alternative medicine
Background A draft version of part 1 (Non‐Motor Aspects of Experiences of Daily Living; nM‐EDL) of the MDS‐UPDRS scale was employed as a secondary outcome in the ADAGIO study, which assessed the effect of rasagiline in early Parkinson's disease (PD) patients. Methods This analysis includes 1,150 untreated PD patients randomized to placebo or rasagiline 1 or 2 mg/day for 36 weeks in the placebo‐controlled phase of ADAGIO who had draft‐nM‐EDL assessments at baseline and week 36. Results Over the 9‐month placebo‐controlled phase of the study, nM‐EDL scores significantly deteriorated from baseline in the placebo group only (0.34 ± 0.10 units; P < 0.001). Compared to the placebo group (n = 583), there was significantly less deterioration in the 1‐mg/day rasagiline group (n = 280; treatment effect: −0.33 units; P < 0.05), whereas the treatment effect in the 2‐mg/day rasagiline group (n = 287) was not statistically significant (−0.25 ± 0.17 units; P = 0.131). Conclusions The nM‐EDL subscale appears sensitive to change in very early PD, and treatment with rasagiline 1 mg/day was associated with significantly less decline in nonmotor experiences of daily living versus placebo. Given that score changes were numerically small, the clinical implications of this effect remain unclear. © 2014 International Parkinson and Movement Disorder Society